The UK National Health Service and Novartis yesterday announced they have entered into an agreement to commercialize the immunotherapy Kymriah (tisagenlecleucel) for patients with a rare type of leukemia (ALL) in the UK, but they have not disclosed the price yet. Importantly, Kymriah is a revolutionary CAR-T (chimeric antigen receptor T cell) therapy that reprograms patients’ immune cells. Its list price is GBP282,000 per patient. The agreement follows by as few as 10 days the market approval granted by European Union authorities. According to NHS, Kymriah could benefit a minimum of 30 patients per year.